| 1. |
|
|
| 2. |
- Joabsson, F., et al.
(författare)
-
Interfacial interaction between sodium dodecyl sulfate and hydrophobically modified ethyl(hydroxyethyl)cellulose. A surface force study
- 2001
-
Ingår i: Langmuir. - : American Chemical Society (ACS). - 0743-7463 .- 1520-5827. ; 17:5, s. 1506-1510
-
Tidskriftsartikel (refereegranskat)abstract
- The effect of addition of sodium dodecyl sulfate (SDS) to a layer of hydrophobically modified ethyl(hydroxyethyl)cellulose (HM-EHEC) preadsorbed on hydrophobized mica has been studied with an interferometric surface force apparatus (SFA). The force between the surfaces was always repulsive on both compression and separation. The range of this force, which is 1500 Angstrom for the HM-EHEC layers, undergoes a non-monotonic change on addition of SDS. Initially, at low SDS concentrations the layer expand, while at higher surfactant concentrations a contraction of the adsorbed layer is observed. At 1.5 mM SDS the range of the force is at maximum, while at 6 mM SDS the layer is significantly thinner than before addition of SDS. The results are discussed in terms of polymer-surfactant interfacial association and competitive adsorption. The data obtained by surface force measurements agree qualitatively with ellipsometry findings on the same system.
|
|
| 3. |
- Rajnavolgyi, E, et al.
(författare)
-
A repetitive sequence of Epstein-Barr virus nuclear antigen 6 comprises overlapping T cell epitopes which induce HLA-DR-restricted CD4(+) T lymphocytes
- 2000
-
Ingår i: International Immunology. - : Oxford University Press (OUP). - 1460-2377 .- 0953-8178. ; 12:3, s. 281-293
-
Tidskriftsartikel (refereegranskat)abstract
- Most human adults carry the Epstein-Barr virus (EBV) and develop immunological memory against the structural and the virus-encoded cellular proteins. The EBV nuclear antigen 6 (EBNA6) elicits cytotoxic T cell responses and it also maintains a persistent antibody response. The majority of sera from EBV-seropositive individuals reacts with a synthetic peptide, p63, comprising 21 amino acids of a repetitive region of EBNA6. CD4(+) T lymphocytes, with specificity for p63, could be recalled from the T cell repertoire of EBV carriers that expressed certain HLA-DR allotypes which were identified as good binders of p63 by an in vitro flow cytometric assay. Analysis of the HLA-DR/p63 interaction by molecular mechanics calculations indicated the presence of multiple overlapping epitopes which were predicted to bind in a HLA-DRB1 allo- and subtype-specific manner. Specific activation of p63-selected long-term CD4(+) T cell cultures resulted in a proliferative response, in the production of IL-2 and in the secretion of high levels of tumor necrosis factor as measured by bioassays. Proliferation and cytokine production of p63-specific T cells could be induced by p63-loaded HLA-DR-matched antigen-presenting cells and by B cells co-expressing relevant HLA-DR molecules and EBNA6. Our results show that peptides of an EBNA6 repeat region induce CD4(+) T cells which can react with EBNA6-carrying cells in many individuals. We suggest that these T(h) cells may be important in conditioning dendritic cells for initiation potent virus-specific immune responses, provide help for EBV-specific B cells, drive IgG isotype switch and support the sustained effector function of memory cytotoxic T lymphocytes.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Thuresson, K, et al.
(författare)
-
Väderbacken 1678
- 2001
-
Ingår i: Plats, landskap, karta. - Stockholm : Stockholm University. - 9197286753 ; , s. 52-53
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
| 7. |
|
|
| 8. |
- Wahlander, K, et al.
(författare)
-
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis
- 2002
-
Ingår i: Thrombosis Research. - 1879-2472. ; 107:3-4, s. 93-99
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: Ximelagatran is a novel, oral direct thrombin inhibitor that is currently being investigated for the prophylaxis and treatment of thromboembolic events. This study evaluated the pharmacokinetics, pharmacodynamics, and clinical effects of melagatran, the active form of ximelagatran, in patients with both deep vein thrombosis (DVT) and pulmonary embolism (PE). Materials and methods: In this open-label study, 12 patients received a fixed dose of 48 mg oral ximelagatran twice daily for 6-9 days. Plasma samples were collected for determination of melagatran concentrations and scintigraphic changes and adverse events were recorded. Results: Peak plasma concentrations of melagatran were attained approximately 2 h after administration of ximelagatran. Melagatran plasma concentration profiles were similar on Days 1, 2, and 6-9. Plasma activated partial thromboplastin time increased following administration of ximelagatran and reached a peak that was approximately twofold higher than the predose activated partial thromboplastin time and correlated with melagatran plasma concentrations (R-2 = 0.69). All but one patient (with malignancy) showed regressed or unchanged lung scintigraphic findings, and six of these demonstrated no, or only minor, perfusion defects at central evaluation after 6-9 days of ximelagatran treatment. Clinical symptoms, including chest pain, dyspnoea, cough, and oedema, and pain in the affected leg, were improved. Ximelagatran was well tolerated with no deaths or severe bleeding events reported during treatment. Conclusion: Treatment with a fixed dose of oral ximelagatran, used without routine coagulation monitoring, showed reproducible pharmacokinetics and pharmacodynamics with a rapid onset of action and promising clinical results in patients with pulmonary embolism.
|
|
